The Economic Impact of Early Discharge Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infecti Amanda Lowney, Alyssa Gould, Jamie Warren Novant Health Rowan Medical Center - Salisbury, NC
Background/Purpose: A significant increase in hospitalizations due to ABSSSI necessitates the need for treatment models focused on facilitation of early discharge and admission avoidance. The increasing prevalence of multi-drug resistant pathogens implicated in ABSSSI limits available treatment strategies. Dalbavancin, a long-acting lipoglycopeptide, offers convenient one-time dosing and provides coverage of the most common pathogens while avoiding nephrotoxicity. The purpose of this study is to identify potential cost savings associated with using dalbavancin for early discharge of patients with ABSSSI.
Methodology: Patients admitted to one of four acute care facilities with a diagnosis of ABSSSI were prospectively screened for early discharge with intravenous dalbavancin. Eligible patients were adult patients with an expected length of stay of at least 3 days, at least one systemic sign of infection, and at least two local signs of infection on admission. Further exploratory analysis was performed on patients who did not meet the inclusion criteria based upon the absence of systemic involvement. This subgroup was considered eligible for admission avoidance. A cost minimization analysis was performed in order to determine the potential cost savings associated with reducing length of stay.
Presentation Objective: Assess the estimated financial impact associated with early discharge on dalbavancin in patients with ABSSSI.
Self-Assessment: Which of the following is not applicable when considering dalbavancin for early discharge of patients with ABSSSI?
